In non-Hodgkin’s lymphoma B cells, Rituximab, an FDA-approved chimeric anti-human CD20 monoclonal antibody, sensitizes resistant tumor cells to drug treatment by inducing RKIP expression leading to down-regulation of ERK phosphorylation and the anti-apoptotic gene Bcl-XL (B-cell lymphoma–extra large) [59]. This evidence concerns the gene PEBP1 and neoplasm.